T
Tomohiro Asai
Researcher at University of Shizuoka
Publications - 147
Citations - 4075
Tomohiro Asai is an academic researcher from University of Shizuoka. The author has contributed to research in topics: Liposome & Small interfering RNA. The author has an hindex of 35, co-authored 140 publications receiving 3445 citations. Previous affiliations of Tomohiro Asai include Hamamatsu Photonics & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Recent advances in siRNA delivery mediated by lipid-based nanoparticles.
TL;DR: The design of LNPs for the improvement of siRNA properties, bioavailability, and pharmacokinetics are described for the development of an effective LNP-based siRNA delivery system and siRNA formulation.
Journal ArticleDOI
Liposomes and nanotechnology in drug development: focus on ocular targets.
TL;DR: The recent data show that intravitreal injection of targeted liposomes encapsulating an angiogenesis inhibitor caused significantly greater suppression of choroidal neovascularization than did the injection of free drug.
Journal ArticleDOI
Particle size-dependent triggering of accelerated blood clearance phenomenon
Hiroyuki Koide,Tomohiro Asai,Kentaro Hatanaka,Takeo Urakami,Takayuki Ishii,Eriya Kenjo,Masamichi Nishihara,Masayuki Yokoyama,Tatsuhiro Ishida,Hiroshi Kiwada,Naoto Oku +10 more
TL;DR: The enhanced blood clearance and hepatic uptake of the test dose (ABC phenomenon) were related to the size of triggering nanoassemblies, which provides important information for developing both drug and gene delivery systems by means of nanocarriers.
Journal ArticleDOI
T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Hiroyuki Koide,Tomohiro Asai,Kentaro Hatanaka,Shuji Akai,Takayuki Ishii,Eriya Kenjo,Tatsuhiro Ishida,Hiroshi Kiwada,Hideo Tsukada,Naoto Oku +9 more
TL;DR: The present study suggests that PEGylated liposomes might be recognized by B cells as a thymus-independent type 2 (TI-2) antigen and provides important information for the future development of liposomal medicines.
Journal ArticleDOI
Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Naoto Oku,Tomohiro Asai,Koh Watanabe,Koichi Kuromi,Mayumi Nagatsuka,Kohta Kurohane,Hironori Kikkawa,Koichi Ogino,Michinori Tanaka,Dai Ishikawa,Hideo Tsukada,Masanobu Momose,Jun Nakayama,Takao Taki +13 more
TL;DR: The usefulness of APRPG-peptide as a tool for anti-neovascular therapy, a novel modality of cancer treatment, is indicated.